



9th November 2006

Seeing Machines Limited
("Seeing Machines" or the "Company")

GLAUCOMA CLINICAL STUDY RE-COMMENCES

Seeing Machines (AIM: SEE), a leading developer of advanced computer based imaging software systems, announces today the commencement of the next phase of the second clinical study (CT2b) for its glaucoma testing device, Truefield, as foreshadowed in the announcement of 30 August 2006 headed 'Glaucoma Project Clinical Study Results'. CT2b will commence on 20 November 2006 and will involve 160 patients in a clinical setting at the Canberra Eye Hospital, Australia.

The commencement of this phase of the study follows the successful completion of 2 scientific studies T13 and T14 at the Canberra Eye Hospital in September and October. These studies confirmed the results of the earlier CT1 study which showed that the device:

- successfully detects the loss of visual field associated with glaucoma; and
- successfully differentiates between those patients with visual field loss and those without, thus providing the basis for a reliable and accurate diagnostic instrument.

The 2 scientific studies also highlighted that the expected improvements in the performance of the technology since the CT1 study had been achieved.

Commenting on the scientific study results Nick Cerneaz, CEO of Seeing Machines said: "These results are very positive and enable us to move forward with our plans for the introduction of the device, firstly with the commencement of the next phase of the clinical study, but also all of the other activities needed to bring the device to market. This device, TrueField, will be the world's first non-contact objective test for glaucoma, testing both eyes in 4 minutes. These are very significant advantages over existing glaucoma diagnostic devices on the market today and we have every reason to be confident about the ultimate commercial success of TrueField. Our aim, which we are pursuing aggressively, is to launch the device during calendar year

2007. We are very grateful for the work of our partners at the Australian National University led by Drs Ted Maddess and Dr Andrew James and the support we receive from the Canberra Eye Hospital. I would also like to acknowledge the work of our own very dedicated staff and also the financial support we receive for the project from the Australian Government's Commercial Ready Program".

--- ENDS ---

Enquiries:

Seeing Machines Limited

Nick Cerneaz, CEO

+61 (0) 2 6125 6501

www.seeingmachines.com

Insinger de Beaufort

Simon Fox

+44 (0) 20 7190 7018

Parkgreen

Communications

Victoria Thomas

+44 (0) 20 7493 3713